Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547804 | 1.00 | KDM4E (0.70) | KDM4EMAPKAPK2CYP1A2TNFMAPT | |
| Hydrochloric Acid SCHEMBL28107495 | 0.98 | KDM4E (0.68) | KDM4EMAPKAPK2CYP1A2TNFMAPT | |
| SCHEMBL27835157 | 0.98 | KDM4E (0.68) | KDM4EMAPKAPK2CYP1A2TNFMAPT | |
| SCHEMBL276518 | 0.83 | KDM4E (1.00) | KDM4EMAPKAPK2CYP1A2MAPTEP300 | |
| SCHEMBL28203494 | 0.81 | KDM4E (0.96) | KDM4EMAPKAPK2CYP1A2MAPTEP300 | |
| SCHEMBL30001948 | 0.78 | TNF (0.53) | KDM4EMAPKAPK2CYP1A2TNFMAPT | |
| SCHEMBL3150717 | 0.78 | TNF (0.53) | KDM4EMAPKAPK2CYP1A2TNFMAPT | |
| SCHEMBL30477305 | 0.76 | TNF (0.55) | KDM4EMAPKAPK2CYP1A2TNFLMNA | |
| SCHEMBL277592 | 0.76 | KDM4E (0.55) | KDM4EMAPKAPK2CYP1A2TNFMAPT | |
| SCHEMBL14893769 | 0.75 | TNF (0.50) | KDM4EMAPKAPK2CYP1A2TNFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232140-B | Tetrahydroquinoline chroman polycyclic compound and preparation method and application thereof | 河南大学 | 2023-06-30 | — | — | CN | claimed |
| CN-115232140-A | Tetrahydroquinoline chroman polycyclic compound and preparation method and application thereof | 河南大学 | 2022-10-25 | — | — | CN | claimed |
| CN-113690436-A | Corrosion inhibitor for zinc cathode of alkaline manganese battery | 浙江野马电池股份有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-112540515-A | Photoresist stripping liquid and preparation method and application thereof | 江苏艾森半导体材料股份有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-106554687-B | A kind of external wall water-and acrylate lotion | 上海保立佳新材料有限公司 | 2018-12-18 | — | — | CN | claimed |
| CN-108697709-A | Methods for treating huntington's disease | PTC医疗公司 | 2018-10-23 | — | — | CN | claimed |
| CN-106966977-A | The synthetic method of 8 isoquinolinols | 徐州医科大学 | 2017-07-21 | — | — | CN | claimed |
| CN-104562037-B | Siliceous macromolecular corrosion inhibitor composition and preparation method thereof | 中国石油化工股份有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-106554687-A | A kind of external wall water-and acrylate emulsion | 上海保立佳新材料有限公司 | 2017-04-05 | — | — | CN | claimed |
| CN-105427953-B | A kind of fire-retardant rat-and-ant proof communication cable that resists cold | 国家电网公司 | 2017-03-29 | — | — | CN | claimed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | claimed |
| CN-105575544-A | Communication cable capable of preventing saline-alkaline corrosion and rat/ant gnawing | STATE GRID SHANDONG LAIYANG POWER SUPPLY COMPANY | 2016-05-11 | — | — | CN | claimed |
| US-20160111696-A1 | METHOD FOR MAKING POLYIMIDE MICROPOROUS SEPARATOR | TSINGHUA UNIVERSITY (CN) | 2016-04-21 | — | — | US | claimed |
| CN-105427953-A | Cold-resistant flame-retardant rat-proof and termite-proof communication cable | STATE GRID CORP CHINA | 2016-03-23 | — | — | CN | claimed |
| CN-105244098-A | Cold-resistant anti-oxidation flame-retardant cable | STATE GRID CORP CHINA | 2016-01-13 | — | — | CN | claimed |
| CN-103383996-B | Preparation method of polyimide micro-pore diaphragm | JIANGSU HUADONG INST OF LI ION BATTERY CO LTD | 2015-07-22 | — | — | CN | claimed |
| CN-104562037-A | Siliceous macromolecular corrosion inhibitor composition and preparation method thereof | CHINA PETROLEUM & CHEMICAL | 2015-04-29 | — | — | CN | claimed |
| CN-104312060-A | Cold-resisting oil-resisting modified fluorine rubber cable sheath material | ANHUI HUAFENG CABLE GROUP CO LTD | 2015-01-28 | — | — | CN | claimed |
| CN-103383996-A | Preparation method of polyimide micro-pore diaphragm | JIANGSU HUADONG INST OF LI ION BATTERY CO LTD | 2013-11-06 | — | — | CN | claimed |
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3978073-B1 | 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES | UBE CORP (JP) | 2025-10-15 | — | — | EP | disclosed |
| CN-114174289-B | Benzotriazole derivatives | ＵＢＥ株式会社 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024153947-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-07-25 | — | — | WO | disclosed |
| CN-117794930-A | KRAS inhibitors | 苏州亚盛药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| CN-112540515-B | Photoresist photoresist stripping solution and preparation method and application thereof | 江苏艾森半导体材料股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023125944-A1 | COMPOUND CONTAINING HETEROCYCLIC RING | 正大天晴药业集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-116375683-A | Diazole derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115232140-B | Tetrahydroquinoline chroman polycyclic compound and preparation method and application thereof | 河南大学 | 2023-06-30 | — | — | CN | disclosed |
| CN-115232140-B | Tetrahydroquinoline chroman polycyclic compound and preparation method and application thereof | 河南大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2023088406-A1 | FUSED IMIDE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023030495-A1 | KRAS INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-03-09 | — | — | WO | disclosed |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| CN-109890797-B | Substituted carbon nucleoside derivatives useful as anticancer agents | 辉瑞公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-4126819-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115697969-A | 7-or 8-hydroxy-isoquinoline and 7-or 8-hydroxy-quinoline derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115697969-A | 7-or 8-hydroxy-isoquinoline and 7-or 8-hydroxy-quinoline derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115697969-A | 7-or 8-hydroxy-isoquinoline and 7-or 8-hydroxy-quinoline derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) | 弗特克斯药品有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| CN-115232140-A | Tetrahydroquinoline chroman polycyclic compound and preparation method and application thereof | 河南大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-115232140-A | Tetrahydroquinoline chroman polycyclic compound and preparation method and application thereof | 河南大学 | 2022-10-25 | — | — | CN | disclosed |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3596051-B1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-04-27 | — | — | EP | disclosed |
| EP-3978073-A1 | BENZOTRIAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3974428-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2022-03-30 | — | — | EP | disclosed |
| CN-114174289-A | Benzotriazole derivatives | 宇部兴产株式会社 | 2022-03-11 | — | — | CN | disclosed |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| CN-113690436-A | Corrosion inhibitor for zinc cathode of alkaline manganese battery | 浙江野马电池股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| WO-2021203028-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2021-03-25 | — | — | US | disclosed |
| CN-112540515-A | Photoresist stripping liquid and preparation method and application thereof | 江苏艾森半导体材料股份有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-10941138-B2 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-03-09 | — | — | US | disclosed |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3765446-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.p.A. (IT) | 2021-01-20 | — | — | EP | disclosed |
| EP-3750890-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Fudan University (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2020241853-A1 | BENZOTRIAZOLE DERIVATIVE | 宇部興産株式会社 | 2020-12-03 | — | — | WO | disclosed |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-19 | — | — | US | disclosed |
| CN-111868035-A | Substituted pyrazole FFA4/GPR120 receptor agonists | 阿克萨姆股份公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200087291-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-19 | — | — | US | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2020-03-19 | — | — | US | disclosed |
| WO-2020035070-A1 | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | 漳州片仔癀药业股份有限公司 | 2020-02-20 | — | — | WO | disclosed |
| EP-3596051-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | Impetis Biosciences Ltd. (IN) | 2020-01-22 | — | — | EP | disclosed |
| EP-3558965-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019175152-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.P.A. (IT) | 2019-09-19 | — | — | WO | disclosed |
| CN-110248933-A | Novel quinoline and isoquinoline derivatives for the treatment of pain and pain related disorders | 埃斯特韦制药股份公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-106536503-B | A kind of tyrosine kinase inhibitor and application thereof | 北京澳合药物研究院有限公司 | 2019-09-06 | — | — | CN | disclosed |
| US-10392351-B2 | Method for preparing nilotinib intermediate | SUZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2019-08-27 | — | — | US | disclosed |
| WO-2019154047-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 复旦大学 | 2019-08-15 | — | — | WO | disclosed |
| CN-109890797-A | It can be used as the substituted carbon nucleoside derivates of anticancer agent | 辉瑞公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-104045552-B | Medicinal compound as neuroprotective agent | 江苏先声药业有限公司 | 2019-06-11 | — | — | CN | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3464249-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| CN-106554687-B | A kind of external wall water-and acrylate lotion | 上海保立佳新材料有限公司 | 2018-12-18 | — | — | CN | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3386511-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| CN-108558852-A | A kind of GOAT inhibitor and its application in fat and diabetes | 王丽萍 | 2018-09-21 | — | — | CN | disclosed |
| CN-108558849-A | A kind of benzo [b] thiophenes and its application in fat and diabetes | 王丽萍 | 2018-09-21 | — | — | CN | disclosed |
| WO-2018167800-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LIMITED (IN) | 2018-09-20 | — | — | WO | disclosed |
| US-20180243328-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-30 | — | — | US | disclosed |
| WO-2018115064-A1 | NEW QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-06-28 | — | — | WO | disclosed |
| EP-3339304-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | Laboratorios del Dr. Esteve, S.A. (ES) | 2018-06-27 | — | — | EP | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| CN-106966977-A | The synthetic method of 8 isoquinolinols | 徐州医科大学 | 2017-07-21 | — | — | CN | disclosed |
| US-9688685-B2 | Method for preparing volasertib and intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-06-27 | — | — | US | disclosed |
| WO-2017100726-A1 | METHODS FOR TREATNG HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| CN-104562037-B | Siliceous macromolecular corrosion inhibitor composition and preparation method thereof | 中国石油化工股份有限公司 | 2017-05-17 | — | — | CN | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| CN-106554687-A | A kind of external wall water-and acrylate emulsion | 上海保立佳新材料有限公司 | 2017-04-05 | — | — | CN | disclosed |
| CN-105427953-B | A kind of fire-retardant rat-and-ant proof communication cable that resists cold | 国家电网公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-106536503-A | Tyrosine kinase inhibitor and uses thereof | 山东轩竹医药科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160311777-A1 | Method for preparing nilotinib intermediate | SUZHOU LIXIN PHARMACEUTICAL CO.,LTD (CN) | 2016-10-27 | — | — | US | disclosed |
| CN-104583196-B | The method that 1,4-dibasic pyridazine analog and treatment lack relevant disease to SMN | 诺华股份有限公司 | 2016-10-12 | — | — | CN | disclosed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | disclosed |
| US-20160293852-A1 | ORGANIC LIGHT EMITTING DIODE | LG CHEM, LTD. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160293852-A1 | ORGANIC LIGHT EMITTING DIODE | LG CHEM, LTD. (KR) | 2016-10-06 | — | — | US | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| CN-105575544-A | Communication cable capable of preventing saline-alkaline corrosion and rat/ant gnawing | STATE GRID SHANDONG LAIYANG POWER SUPPLY COMPANY | 2016-05-11 | — | — | CN | disclosed |
| US-20160111696-A1 | METHOD FOR MAKING POLYIMIDE MICROPOROUS SEPARATOR | TSINGHUA UNIVERSITY (CN) | 2016-04-21 | — | — | US | disclosed |
| US-20160111696-A1 | METHOD FOR MAKING POLYIMIDE MICROPOROUS SEPARATOR | TSINGHUA UNIVERSITY (CN) | 2016-04-21 | — | — | US | disclosed |
| US-20160111696-A1 | METHOD FOR MAKING POLYIMIDE MICROPOROUS SEPARATOR | TSINGHUA UNIVERSITY (CN) | 2016-04-21 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| CN-105427953-A | Cold-resistant flame-retardant rat-proof and termite-proof communication cable | STATE GRID CORP CHINA | 2016-03-23 | — | — | CN | disclosed |
| CN-105244098-A | Cold-resistant anti-oxidation flame-retardant cable | STATE GRID CORP CHINA | 2016-01-13 | — | — | CN | disclosed |
| CN-104003989-B | Fu Lasai for and the preparation method of intermediate | SUZHOU MINGYUE MEDICAL TECHNOLOGY CO., LTD. (CN) | 2015-11-11 | — | — | CN | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| CN-103383996-B | Preparation method of polyimide micro-pore diaphragm | JIANGSU HUADONG INST OF LI ION BATTERY CO LTD | 2015-07-22 | — | — | CN | disclosed |
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-9028562-B2 | Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor | L'OREAL (FR) | 2015-05-12 | — | — | US | disclosed |
| US-9028562-B2 | Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor | L'OREAL (FR) | 2015-05-12 | — | — | US | disclosed |
| CN-104562037-A | Siliceous macromolecular corrosion inhibitor composition and preparation method thereof | CHINA PETROLEUM & CHEMICAL | 2015-04-29 | — | — | CN | disclosed |
| CN-103694176-B | Preparation method of nilotinib intermediate | Suzhou lixin pharmaceutical co ltd | 2015-02-18 | — | — | CN | disclosed |
| CN-104312060-A | Cold-resisting oil-resisting modified fluorine rubber cable sheath material | ANHUI HUAFENG CABLE GROUP CO LTD | 2015-01-28 | — | — | CN | disclosed |
| EP-2797918-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| CN-104045552-A | Medicinal compound as neuroprotective agent | SHANGHAI SIMCERE PHARMACEUTICAL RES CO LTD | 2014-09-17 | — | — | CN | disclosed |
| CN-104003989-A | Preparation method of Volasertib and intermediates thereof | XU XUENONG | 2014-08-27 | — | — | CN | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| CN-103694176-A | Preparation method of nilotinib intermediate | Suzhou lixin pharmaceutical co ltd | 2014-04-02 | — | — | CN | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | L'OREAL (FR) | 2014-02-13 | — | — | US | disclosed |
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | L'OREAL (FR) | 2014-02-13 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| CN-103383996-A | Preparation method of polyimide micro-pore diaphragm | JIANGSU HUADONG INST OF LI ION BATTERY CO LTD | 2013-11-06 | — | — | CN | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| WO-2013143597-A1 | DEMETHYLASE ENZYMES INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | WO | disclosed |
| EP-2079728-B1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | AMGEN INC (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| WO-2013055910-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2332917-B1 | Compounds for PIM kinase inhibition and for treating malignancy | SYGNIS BIOSCIENCE GMBH & CO KG (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2332917-B1 | Compounds for PIM kinase inhibition and for treating malignancy | SYGNIS BIOSCIENCE GMBH & CO KG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8022061-B2 | 5-(Methoxymethyl)-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide; for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2332917-A1 | Compounds for PIM kinase inhibition and for treating malignancy | Sygnis Bioscience GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332917-A1 | Compounds for PIM kinase inhibition and for treating malignancy | Sygnis Bioscience GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011057784-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057784-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2011-05-19 | — | — | WO | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20110009394-A1 | TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100310537-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100310535-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100298559-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| EP-2233561-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233468-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2228434-A1 | AMPLIFICATION METHOD FOR HEMATOPOIETIC STEM CELLS WITH HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2203429-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | AMNESTIX, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7595415-B2 | α-Substituted vinyltin compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2079728-A1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | Amgen Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| CN-100513405-C | Chiral ionic compound containing pyrrolidinyl radical and its preparation and application | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-07-15 | — | — | CN | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| WO-2009057827-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | AMGEN INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008045484-A1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7332511-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| CN-1974566-A | Chiral ionic compound containing pyrrolidinyl radical and its prepn and application | UNIV ZHEJIANG POLYTECHNIC (CN) | 2007-06-06 | — | — | CN | disclosed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1720868-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1706149-A2 | LIPOSOME COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS | ALZA CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7112337-B2 | Liposome composition for delivery of nucleic acid | ALZA CORPORATION (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| US-20050191344-A1 | Liposome composition for delivery of therapeutic agents | ALZA CORPORATION | 2005-09-01 | — | — | US | disclosed |
| WO-2005077944-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005070466-A2 | LIPOSOME COMPOSITION FOR DELIVERY OF THERAPEUTIC AGENTS | ALZA CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| EP-1465599-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA Corporation (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040197390-A1 | Neutral-cationic lipid for systemic delivery of factor VIII gene | HUANG SHI-KUN (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040166150-A1 | Neutral-cationic lipid for systemic delivery of Factor VIII gene | HUANG SHI-KUN (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-08-12 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004007459-A2 | NAPHTHOL, QUINOLINE AND ISOQUINOLINE-DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003053409-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF NUCLEIC ACID | ALZA CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030031704-A1 | Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic | ALZA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| WO-2002096390-A1 | NEUTRAL-CATIONIC LIPID FOR SYSTEMIC DELIVERY OF FACTOR VIII GENE | ALZA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0236880-B1 | Penem derivatives | ERBA CARLO SPA (IT) | 1994-07-20 | — | — | EP | disclosed |
| EP-0327239-B1 | 1-carbacephalosporin antibiotics | LILLY CO ELI (US) | 1994-06-22 | — | — | EP | disclosed |
| CN-1021735-C | Process for producing carbapenem compound | ERBA FARMITALIA (IT) | 1993-08-04 | — | — | CN | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| EP-0232623-B1 | 1-CARBACEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0238060-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS | Banyu Pharmaceutical Co., Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-5019571-A | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1991-05-28 | — | — | US | disclosed |
| US-5011938-A | Antimicrobials | ELI LILLY AND COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0201206-B1 | PENEM DERIVATIVES | FARMITALIA CARLO ERBA S.r.l. (IT) | 1990-07-25 | — | — | EP | disclosed |
| US-4940718-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| US-4892942-A | 1-CARBA (DETHIA)CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4886793-A | PENICILLINS; HUMANS OR ANIMALS | FARMITALIA CARLO ERBA, S.R.L. (IT) | 1989-12-12 | — | — | US | disclosed |
| US-4863914-A | BACTERICIDES, ANTIBIOTICS | FARMITALIA CARLO ERBA (IT) | 1989-09-05 | — | — | US | disclosed |
| EP-0327239-A1 | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4814328-A | Cephalosporin derivatives, and antibacterial agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-03-21 | — | — | US | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| US-4782155-A | ISOQUINOLINE SALTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| EP-0238060-A2 | Cephalosporin derivatives, processes for their preparation and antibacterial agents | Banyu Pharmaceutical Co., Ltd. (JP) | 1987-09-23 | — | — | EP | disclosed |
| EP-0236880-A2 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-09-16 | — | — | EP | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| CN-86102350-A | Process for the preparation of novel * compounds | ERBA FARMITALIA (IT) | 1986-12-31 | — | — | CN | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
| EP-0201206-A1 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1986-11-12 | — | — | EP | disclosed |
| CN-86103619-A | The preparation method of the bicyclic pyrazolidinones that 7-replaces | — | 1986-10-29 | — | — | CN | disclosed |
| US-4594351-A | A 4-diphenylmethyl-1-iminomethylpiperidine compound | MCNEILAB, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| US-4528293-A | Heteroaromatic derivatives of iminomethyl piperidines and use to inhibit gastric acid secretion | MCNEILAB, INC. (US) | 1985-07-09 | — | — | US | disclosed |
| US-4478820-A | Anilino-substituted isoquinoline quinones, pharmaceutical compositions and method of use thereof | ELI LILLY AND COMPANY (US) | 1984-10-23 | — | — | US | disclosed |
| EP-0107364-A2 | 7-Anilinoisoquinoline-5,8-quinones | ELI LILLY AND COMPANY (US) | 1984-05-02 | — | — | EP | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
| US-4215219-A | CHELATING AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1980-07-29 | — | — | US | disclosed |
| US-4085261-A | CHELATING AGENT WITH A STYRENE POLYMER BACKBONE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-04-18 | — | — | US | disclosed |
| US-4085261-A | CHELATING AGENT WITH A STYRENE POLYMER BACKBONE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197390-A1 | Neutral-cationic lipid for systemic delivery of factor VIII gene | F13B, F13A1, F8 | KDM4E 2463/4885MAPKAPK2 4104/4885CYP1A2 1225/4885 |
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | KDM4E 502/4885MAPKAPK2 1502/4885CYP1A2 350/4885 |
| US-20050191344-A1 | Liposome composition for delivery of therapeutic agents | PHOSPHO1, LIPA, SGMS1 | KDM4E 3885/4885MAPKAPK2 3872/4885CYP1A2 4878/4885 |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | KDM4E 988/4885MAPKAPK2 2535/4885CYP1A2 1076/4885 |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | KDM4E 47/4885MAPKAPK2 1755/4885CYP1A2 3501/4885 |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | KDM4E 53/4885MAPKAPK2 1047/4885CYP1A2 2522/4885 |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | FFAR4, FFAR3, FFAR1 | KDM4E 3733/4885MAPKAPK2 697/4885CYP1A2 1736/4885 |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | KDM4E 3417/4885MAPKAPK2 1206/4885CYP1A2 1718/4885 |
| US-20140041133-A1 | DYE COMPOSITION USING A 2-HYDROXYNAPHTHALENE, (ACYLAMINO)PHENOL OR QUINOLINE COUPLER IN A FATTY-SUBSTANCE-RICH MEDIUM, DYEING PROCESS AND DEVICE THEREFOR | HADHB, HADH, FABP4 | KDM4E 1743/4885MAPKAPK2 1863/4885CYP1A2 133/4885 |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KDM4E 4218/4885MAPKAPK2 1239/4885CYP1A2 2081/4885 |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | KDM4E 1275/4885MAPKAPK2 154/4885CYP1A2 3274/4885 |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KDM4E 4480/4885MAPKAPK2 2152/4885CYP1A2 429/4885 |
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | KDM4E 3009/4885MAPKAPK2 1239/4885CYP1A2 4044/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | KDM4E 4422/4885MAPKAPK2 2105/4885CYP1A2 434/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KDM4E 4854/4885MAPKAPK2 2489/4885CYP1A2 659/4885 |
| US-20100160297-A1 | COMPOUNDS FOR PIM KINASE INHIBITION AND FOR TREATING MALIGNANCY | PIM1, PIM2, PIM3 | KDM4E 1346/4885MAPKAPK2 26/4885CYP1A2 1217/4885 |
| US-10941138-B2 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | CACNA1B, SCN2A, CACNA1C | KDM4E 3533/4885MAPKAPK2 1514/4885CYP1A2 529/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KDM4E 4486/4885MAPKAPK2 2213/4885CYP1A2 418/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | KDM4E 61/4885MAPKAPK2 1074/4885CYP1A2 2244/4885 |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | GLP1R, GPR119, NAT1 | KDM4E 4209/4885MAPKAPK2 1680/4885CYP1A2 6/4885 |
| US-20100310535-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | KDM4E 2378/4885MAPKAPK2 4786/4885CYP1A2 2963/4885 |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | KDM4E 40/4885MAPKAPK2 1819/4885CYP1A2 3839/4885 |
| US-20030031704-A1 | Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic | DLST, LIPA, DNAJC10 | KDM4E 3171/4885MAPKAPK2 3986/4885CYP1A2 4783/4885 |
| US-20100298559-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | C5, C9, CCNE1 | KDM4E 2758/4885MAPKAPK2 2961/4885CYP1A2 731/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | KDM4E 4435/4885MAPKAPK2 1568/4885CYP1A2 2411/4885 |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | KDM4E 2891/4885MAPKAPK2 2710/4885CYP1A2 2585/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | KDM4E 1275/4885MAPKAPK2 154/4885CYP1A2 3274/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | KDM4E 988/4885MAPKAPK2 2535/4885CYP1A2 1076/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | KDM4E 2891/4885MAPKAPK2 2710/4885CYP1A2 2585/4885 |
| US-10392351-B2 | Method for preparing nilotinib intermediate | ABL1, PRMT5, NPM1 | KDM4E 874/4885MAPKAPK2 1578/4885CYP1A2 811/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | KDM4E 1371/4885MAPKAPK2 4001/4885CYP1A2 84/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | KDM4E 61/4885MAPKAPK2 1081/4885CYP1A2 2128/4885 |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | KDM4E 47/4885MAPKAPK2 1755/4885CYP1A2 3501/4885 |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | KDM4E 2378/4885MAPKAPK2 4796/4885CYP1A2 3137/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | KDM4E 4218/4885MAPKAPK2 1239/4885CYP1A2 2081/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | KDM4E 2891/4885MAPKAPK2 2710/4885CYP1A2 2585/4885 |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | KDM4E 4616/4885MAPKAPK2 1982/4885CYP1A2 2323/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KDM4E 4480/4885MAPKAPK2 2152/4885CYP1A2 429/4885 |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | KDM4E 3762/4885MAPKAPK2 603/4885CYP1A2 635/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | KDM4E 3733/4885MAPKAPK2 697/4885CYP1A2 1736/4885 |
| US-20100310537-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | KDM4E 2378/4885MAPKAPK2 4796/4885CYP1A2 3137/4885 |
| US-20220259223-A1 | BENZOTRIAZOLE DERIVATIVE | KEAP1, NFE2L2, BACH1 | KDM4E 729/4885MAPKAPK2 327/4885CYP1A2 622/4885 |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | LIPC, GPR119, VIP | KDM4E 747/4885MAPKAPK2 2125/4885CYP1A2 543/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KDM4E 4480/4885MAPKAPK2 2152/4885CYP1A2 429/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | KDM4E 4212/4885MAPKAPK2 1800/4885CYP1A2 1691/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | KDM4E 988/4885MAPKAPK2 2535/4885CYP1A2 1076/4885 |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | KDM4E 1446/4885MAPKAPK2 1309/4885CYP1A2 3293/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | KDM4E 2891/4885MAPKAPK2 2710/4885CYP1A2 2585/4885 |
| US-20200087281-A1 | FUSED BICYCLIC COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | GPR119, GPR65, GPR88 | KDM4E 4800/4885MAPKAPK2 2231/4885CYP1A2 775/4885 |
| US-20170073350-A1 | Method for Preparing Volasertib and Intermediate thereof | CDK8, MDK, WEE1 | KDM4E 204/4885MAPKAPK2 292/4885CYP1A2 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.